Hurley Capital
CORT icon

Hurley Capital’s Corcept Therapeutics CORT Stock Holding History

Hurley Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.5K Hold
100
– – 0.01% 324
2026
Q2 		$8.7K Hold
100
– – ﹤0.01% 340
2026
Q1 		$4.03K Hold
100
– – ﹤0.01% 482
2025
Q4 		$3.48K Hold
100
– – ﹤0.01% 476
2025
Q3 		$8.31K Buy
+100
New +$7.24K ﹤0.01% 383

Other funds holding CORT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Ingalls & Snyder LLC
Ingalls & Snyder LLC New York $3.91B AUM 60.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Parallel Advisors
Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Hurley Capital's CORT Position: Q3 2026 in Review

Hurley Capital held its Corcept Therapeutics (CORT) position steady in Q3 2026 at 100 shares worth $11.5K. The position accounts for 0.01% of the portfolio, ranked #324.

Hurley Capital first reported a position in CORT in Q3 2025 and has held it in 5 quarters since. 403 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Hurley Capital held 100 shares of Corcept Therapeutics worth $11.5K as of Q3 2026.
  • Hurley Capital left its Corcept Therapeutics share count unchanged in Q3 2026.
  • Corcept Therapeutics made up 0.01% of Hurley Capital's portfolio in Q3 2026, its #324 holding.
  • Hurley Capital first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • 403 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Hurley Capital's 13F filing for Q3 2026, filed 5 Nov 2026.